Downregulation of p21/WAF1 is related to advanced and dedifferentiated laryngeal squamous cell carcinoma

Journal of Clinical Pathology

Volumn 52, Issue 6, 1999, Pages 440-444

  Hirvikoski, P ^a   Kellokoski, J K ^a   Kumpulainen, E J ^b   Virtaniemi, J A ^b   Johansson, R T ^b   Kosma, V M ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Laryngeal neoplasms; p21 WAF1; Prognosis

Indexed keywords

CYCLINE; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION;

EID: 0033012543     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.52.6.440     Document Type: Article

References (43)

1. Sessions R, Harrison L, Hong WK. Tumors of the larynx and hypopharynx. In: DeVita VTJ, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 4th ed. Philadelphia: JB Lippincott C, 1993:631-55.
2. Dolcetti R, Doglioni C, Maestro R, et al. p53 over- expression is an early event in the development of human squamous-cell carcinoma of the larynx: genetic and prognostic implications. Im J Cancer 1992;52:178-82.
3. Hirvikoski P, Kumpulainen E, Virtaniemi J, et al. p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma. J Clin Oncol 1997;15: 3111-20.
4. Spafford MF, Koeppe J, Pan Z, et al. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1996;122: 627-32.
5. Pruneri G, Pignataro L, Carboni N, et al. Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous cell carcinoma. Int J Cancer 1998;79:263-8.
6. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75: 817-25.
7. Doglioni C, Pelosio P, Laurino L, et al. p21/Waf1/Cip1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol 1996,179:248-53.
8. Harada N, Gansauge S, Gansauge F, et al. Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21 WAF/CIP1 in pancreatic cancer. Br J Cancer 1997;76:299-305.
9. Wakasugi E, Kobayashi T, Tamaki Y, et al. p21 (Waf1/Cip1) and p53 protein expression in breast cancer. Am J Clin Pathol 1997;107:681-91.
10. DiGiuseppe JA, Redston MS, Yeo CJ, et al. p53- independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995;147:884-8.
11. Tron V, Tang L, Yong W, et al. Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21 WAF-1 in human cutaneous squamous cell carcinoma. Am J Pathol 1996;149:1139-46.
12. Yasui W, Akama Y, Kuniyasu H, et al. Expression of cyclin- dependent kinase inhibitor p21 WAD1/CIP1 in non- neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol 1996,180:122-8.
13. Nadal A, Jares P, Cazorla M, et al. p21 WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J Pathol 1997;183:156-63.
14. Cox L. Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21 Cip1/WAF1/Sdi1. J Pathol 1997;183:134-40.
15. Hermanek P, Sobin LH, eds. UICC International Union Against Cancer: TNM classification of malignant tumors, 4th ed, 2nd revision, 1992.
16. Karnofsky DA, Ableman WH, Craver LF, et al. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948:1:634-56.
17. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
18. Hirvikoski P, Kumpulainen E, Virtaniemi J, et al. Enhanced apoptosis correlates with poor survival in patients with laryngeal cancer but not with cell proliferation, bcl-2 or p53 expression. Eur J Cancer (in press).
19. Haapasalo H, Collan Y, Pesonen E. Volume corrected mitotic index (M/V index)-the standard of mitotic activity in neoplasms. Path Res Pract 1989,185:551-4.
20. Erber R, Klein W, Andl T, et al. Aberrant p21 CIP1/WAF1 protein accumulation in head-and-neck cancer. Int J Cancer (Pred Oncol) 1997;74:383-9.
21. Diab S, Yu Y-Y, Hilsenbeck D, et al. WAF1/CIP1 protein expression in human breast tumors. Breast Cancer Res Treat 1997;1997:99-103.
22. Melhelm M, Law J, El-Ashmawy L, et al. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 1995;146;1170-7.
23. Hall P, Lane D. p53 in tumour pathology: can we trust immunohistochemistry? Revised! J Pathol 1994;172:1-4.
24. Ory K, Legros Y, Auguin C, et al. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. Embo J 1994;13:3496-504.
25. el-Deiry W, Tokino T, Waldman T, et al. Topological control of p2l WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995;55:2910-19.
26. Werness B, Wang H-Q, Chance J, et al. p53-independent expression of p21 waf1/cip1 in preinvasive and invasive squamous neoplasms of the uterine cervix. Mod Pathol 1997;10:578-84.
27. Backe J, Gassel A, Hauber K, et al. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int J Gynecol Pathol 1997;16:361-8.
28. Harper J, Adami GW, Keyomarsi K, et al. The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
29. Brugarolas J, Bronson R, Jacks T. p21 in a critical DCK2 regulator essential for proliferation control in Rb-deficient cells. J Cell Biol 1998;141:503-14.
30. Dimri GP, Nakanishi M, Desprez PY, et al. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol 1996;16:2987-97.
31. Haines D, Landers J, Engle L. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol 1994;14:1171-8.
32. Pruneri G, Pignataro L, Carboni N, et al. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation. Mod Pathol 1997;10:785-92.
33. Gomez-Manzano C, Fueyo J, Kyritsis A, et al. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 1997;89:1036-44.
34. Kawasaki T, Tomita Y, Bilirn V, et al. Abrogation of apoptosis induced by DNA-damaging agents in human bladder- cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. Int J Cancer 1996;68:501-5.
35. Ohashi K, Nemoto T, Eishi Y, et al. Expression of the cyclin dependent kinase inhibitor p21 WAF1/CIP1 in oesophageal squamous cell carcinomas. Virchows Arch 1997;430: 389-95.
36. Miyashita T, Krajewshi M, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1997;9:1799-805.
37. Komiya T, Hosono Y, Hirashima T, et al. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 1997;3:1831-5.
38. Wang A, Yoshimi N, Ino N, et al. WAF1 expression and p53 mutations in human colorectal cancers. J Cancer Res Clin Oncol 1997,123:118-23.
39. Moskaluk CA, Heitmiller R, Zahurak M, et al. p53 and p21 (Waf1/Cip1/Sdi1) gene products in Barrett esophagus and udenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol 1996;27: 1211-20.
40. Byrne RL, Horne CH, Robinson MC, et al. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol 1997;79:190-5.
41. Gomoyo Y, Ikeda M, Osaki M, et al. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997;79:2067-72.
42. Ito K, Sasano H, Matsunaga G, et al. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 1997;183:318-24.
43. Jin Y-T, Kayser S, Kemp B, et al. The prognostic significance of the biomarkers p21 WAF1/CIP1, p53, and bcl-2 in laryngeal squamous cell carcinoma. Cancer 1998;82:2159-65.